Sentences with phrase «federal benefit programs»

You may lose eligibility for other student aid and assistance under most federal benefit programs.

Failure to meet these limits would trigger automatic, across - the - board cuts to federal benefit programs, including Social Security.

According to an August report by the Congressional Budget Office (CBO), debt will likely continue to grow as spending for large federal benefit programs — Social Security, Medicare and the like — outpaces revenue.

Comment: A number of commenters expressed concern that the proposed rule would negatively impact state and federal benefits programs, particularly social security and workers» compensation.

Not exact matches

Morneau said nine out of 10 recipients of child benefits would do better under the new program than they were previously; a family of two children earning $ 90,000 per year will get a tax - free bonus of $ 5,650 per year from the federal government, an increase of $ 2,500 per year compared with Harper's child - subsidy regime.

The SHOP program is a federal health benefits program that small business owners can purchase group coverage on a discount.

Such Constitutional protections have ensured that federal programs such as Medicare, the Veteran Administration's TRICARE system (which provides benefits for active duty members of the military and their families), and the Emergency Medical Treatment and Active Labor Act (EMTALA) apply the same rules to everyone they cover.

«They undoubtedly are dependent on some special legislation or some under - the - table benefits with Medicaid and with education programs going forward that the federal deficit will have to fund,» he says.

The COLA also affects benefits for about 4 million disabled veterans, 2.5 million federal retirees and their survivors, and more than 8 million people who get Supplemental Security Income, the disability program for the poor.

It requires that «no person in the United States shall, on the basis of sex, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any education program or activity receiving federal financial assistance.»

Trump signed the Reducing Poverty in America by Promoting Opportunity and Economic Mobility executive order on Tuesday, directing federal agencies to expand work requirements for those who receive benefits from government assistance programs such as Medicaid, SNAP, and public housing.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Borrowers who refinance federal student loans with private lenders lose access to borrower benefits like access to income - driven repayment programs and the potential to qualify for loan forgiveness after 10, 20 or 25 years of payments.

The commission recommended several reforms including reforming civilian and military retirement programs, reducing agricultural program spending, eliminating in - school subsidies in federal student loan programs, and giving the Pension Benefit Guarantee Corporation the authority to increase premiums.

Keep in mind that if a borrower chooses to refinance federal student loans through a private lender, they will lose the protection and benefits of federal student loan programs.

But if one of the most popular federal programs does survive in its current form — and that is a big if — the average millennial married couple could actually receive nearly double the average Social Security benefits that current retirees collect, according to a...

One of the most notable benefits with federal student loans is the ability to enroll in one of eight different repayment programs.

For its part, the federal government, from the earliest census in 1790 to the creation of New Deal social welfare programs, has long relied on aggregate as well as individual data to distribute resources and administer benefits.

Direct program expenses were up $ 1.0 billion (5.5 %), primarily due to the timing of payments as well as an increase in federal government employee pension and other future benefit liabilities, reflecting the impact of lower interest rates.

First, there are a number of components of federal program expenses that are sensitive to economic developments, most notably employment insurance benefits.

This benefit only applies to the Federal Direct Loans Program.

In FY 2014, executives benefited from an upward adjustment for the lost sales attributed to cuts in the federal food stamp program, even after executives had publicly downplayed any potential impact.

Premium revenues continue to be included as part of the federal government's budgetary revenues and program expenses, both benefits and administration costs, continue to be part of the federal government's total expenses.

However, many analysts feel that for the long - term stock investor, modestly higher interest rates can still benefit stock the slightly Federal Reserve's stimulus program.

Premium revenues will continue to be included as part of the federal government's budgetary revenues and program expenses, both benefits and administration costs, will continue to be part of the federal government's total expenses.

For example, borrowers with federal student loans can take advantage of federal income - driven repayment programs, or benefits like loan forgiveness, which borrowers with private student loans typically don't have access to.

Instead, the federal government has introduced changes to programs (Canada Health Transfer, elderly benefits, etc.) in the Budget Implementation Bill, without providing a proper context for the need for change.

Wells Fargo and other banks that benefited from the federal $ 245 billion Troubled Asset Relief Program are required to participate in HAMP.

Other factors to consider when comparing federal and private student loans include borrower benefits not offered by private lenders, such as access to income - driven repayment programs and the potential to qualify for loan forgiveness.

fully interim federal health program provides limited temporary health benefits refugees refugee claimants;

The curbs come in the wake of the US Federal Reserve's hint that it might start tapering quantitative easing (QE), a program that has greatly benefited India.

Other direct program spending, consisting of operating expenses for Crown corporation, defence and all other departments and agencies, increased $ 2.3 billion (4.2 %), primarily reflecting increases in federal government employee pension and other future benefit liabilities, reflecting the impact of lower interest rates.

In 1992, the federal government consolidated the Family Allowance Program and Child Tax Credit (see above) with a new Child Tax Benefit.

However, the Liberal platform also envisaged temporary deficits to finance higher spending on social programs such as child benefits, a higher Guaranteed Income Supplement for single seniors, public health care, child care and First Nations programs, and did not increase overall federal tax revenues.

One form of federal support for child care is maternity and parental benefits offered through the federal Employment Insurance Program (EI).

This new benefit system is a joint federal - provincial / territorial program, administered by the federal government.

Total federal government expenses consist of four major components: major transfers to persons (old age security, employment insurance benefits and children's benefits); major transfers to other levels of government (Canada Health Transfer, Canada Social Transfer, Fiscal arrangements, Alternative payments for standing programs, and Gas Tax Fund), direct program expenses (other transfers, Crown corporation expenses, and departmental and agency operating and capital expenses) and public debt charges.

As they return to the nation's capital Tuesday from the monthlong summer recess, members of Congress have only weeks to fund the federal government, raise the debt ceiling, and reauthorize a health insurance program that benefits thousands of Maryland children.

Have federal student loans and don't plan to use federal benefits such as income - driven repayment and loan forgiveness (you'll lose access to those programs if you refinance)

Those are two very small programs (combined, not even 1 % of teh federal budget) that have paid us significant benefits over the years.

«This decision again demonstrates the need for enactment of the No Taxpayer Funding for Abortion Act, which would permanently prevent taxpayer subsidies for abortion - covering health plans, both in ObamaCare and in other federal health benefits programs.»

Legal requirements for accessibility to institutions which receive federal funds are listed in Section 504 of the Rehabilitation Act of 1973; it states that «no otherwise qualified handicapped individual... shall, solely by reason of his handicap, be excluded from the participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving federal financial assistance.»

By law all children have the right to benefit from certain federal programs, but the voucher system — through which funds can be spent to benefit the school, not just the student — is both unconstitutional and poor public policy.

The company also benefits from federal rebate programs.

But the federal agriculture minister David Littleproud has hit back, saying the aid program has mutual benefits for Australian cattle producers who rely on a healthy, sustainable live trade to Vietnam.

j Major benefit programs not included in the core analysis, for reasons explained in the text, include civil - service retirement and other federal civilian retirement programs ($ 73 billion), military retirement ($ 51 billion), and veterans» compensation, pensions, and readjustment benefits ($ 56 billion).

It includes every entitlement or mandatory benefit program with annual federal and state expenditures of over $ 10 billion other than veterans» and federal retirement programs.

We are actively engaged in connecting eligible Marylanders with federal nutrition program benefits and available state and local resources.

Brooke ensures that the policies and practices of Maryland state and local agencies and school districts are designed to allow low - income families and individuals maximum access to nutrition programs; and that the state, counties, school districts, and community - based providers take advantage of options in federal law to maximize access and benefits.

cFPL = Federal Poverty Level: a measure of income level for determining financial eligibility for some welfare programs and benefits